VP, Health Economics and Access Strategy at HeartFlow

San Francisco, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

NoVisa

Medical Technology, HealthcareIndustries

Requirements

The candidate must possess exceptional communication skills with a proven track record of leading cross-functional teams to achieve successful coding, coverage, and payment for innovative healthcare technologies. A deep understanding of reimbursement mechanisms across markets, with specific expertise in at-risk asymptomatic populations, is required. Strong leadership and organizational skills with the ability to build and lead a high-performing team composed of internal staff and external consultants are also necessary.

Responsibilities

The Vice President of Health Economics and Market Access Strategy will lead the development and execution of comprehensive strategies to secure coding, coverage, and payment for Heartflow’s future portfolio of products and services. This role involves leading market access initiatives, aligning market access insights with organizational priorities, and designing communication tools that articulate the clinical and economic value of HeartFlow’s technologies. The position also requires driving evidence generation strategies, engaging senior leaders and payers to secure coverage and negotiate contracts, fostering payer partnerships, anticipating market trends, and educating cross-functional teams on reimbursement and market access strategies.

Skills

Health Economics

Market Access

Strategy Development

Cost-Effectiveness Analysis

Stakeholder Engagement

Reimbursement

Coding

HeartFlow

Non-invasive cardiac testing for heart disease

About HeartFlow

HeartFlow provides a non-invasive cardiac test that helps visualize a patient's coronary arteries in detail. This technology allows physicians to diagnose and treat heart disease more effectively without the need for invasive procedures, which reduces risks for patients and costs for healthcare providers. HeartFlow's main clients are healthcare professionals seeking safer diagnostic methods. The company offers several analyses, including FFRCT Analysis and Plaque Analysis, all of which have received FDA clearance and are available in multiple countries, including the United States, the United Kingdom, Japan, and Canada. Unlike many competitors, HeartFlow focuses on providing a comprehensive suite of analyses that enhance treatment planning. The goal of HeartFlow is to improve cardiovascular care by making it safer and more efficient for both patients and healthcare providers.

Redwood City, CaliforniaHeadquarters

2010Year Founded

$858.5MTotal Funding

SERIES_FCompany Stage

HealthcareIndustries

501-1,000Employees

Benefits

Remote Work Options

Stock Options

401(k) Company Match

Risks

Emerging AI-driven competitors could threaten HeartFlow's market share.

Algorithmic bias in AI models could lead to inaccurate diagnoses.

Integration into healthcare systems may face resistance due to complexity and cost.

Differentiation

HeartFlow offers the only combined anatomy, physiology, and plaque analysis for heart disease.

HeartFlow's non-invasive FFRCT Analysis is FDA-cleared and widely available globally.

HeartFlow's AI-driven technology provides personalized 3D heart models for precise diagnostics.

Upsides

HeartFlow closed a $215 million Series F funding round in April 2023.

The global non-invasive cardiac imaging market is projected to grow significantly.

HeartFlow's technology aligns with the trend towards value-based care in healthcare.

Land your dream remote job 3x faster with AI

Try Jobo Free